上海大学发表最新Cell子刊论文

Core Viewpoint - The article discusses the development of a biomimetic nanoimmunotherapy that induces PANoptosis to reshape the desmoplastic tumor microenvironment, enhancing anti-tumor immunity and reducing recurrence risk while inhibiting metastasis [3][8]. Group 1: Challenges in Cancer Immunotherapy - Dendritic cell (DC)-based vaccines face significant challenges in solid tumors, including the lack of tumor-specific antigens and the immunosuppressive stroma present in these tumors [5][6]. - Traditional DC vaccines have limited clinical success due to issues such as antigen degradation and immune tolerance, prompting the exploration of hybrid cells formed by fusing DCs with tumor cells [5][6]. Group 2: Innovative Approaches - The study introduces a therapeutic nano-vaccine, UCNP@MOF@MI@FM (UMMF), which combines dendritic cell and tumor hybrid cell membranes, co-loaded with MTH1 inhibitors and tetrahydrobiopterin (BH4) [6][7]. - This platform aims to induce immunogenic cell death (ICD) through PANoptosis, enhancing the activation of cytotoxic T lymphocytes (CTLs) and reprogramming the tumor microenvironment [6][7]. Group 3: Key Findings - The biomimetic nano-vaccine triggers reactive oxygen species (ROS)-induced immunogenic PANoptosis in a spatiotemporal manner [8]. - Near-infrared (NIR) light programming therapy is effective in reshaping the immunosuppressive tumor microenvironment [8]. - The synergistic effect of BH4 with the UMMF nano-vaccine can combat immune therapy resistance [8].